Cancer biomarkers market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million
Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions